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Platelets are critically important for primary hemosta-sis after vascular injury and are pivotal elements in the 
development of acute thrombotic occlusion and subsequent 
myocardial infarction and ischemic stroke.1,2 Moreover, plate-
lets may contribute to the pathophysiology of disorders not 
directly related to hemostasis or thrombosis, such as cancer,3 
inflammation,4,5 host–pathogen interaction,5,6 and lymphatic 
development.7 Platelets are activated by a wide variety of 
stimulators, such as subendothelial collagen, ADP released 
from activated platelets, or activated thrombin and collagen-
related peptide (CRP).8–10 After activation, platelets secrete 
their granules, undergo cell membrane scrambling with 
phosphatidylserine exposure, aggregate, and form thrombi 
resulting in vascular occlusion.11 Thereby phosphatidylserine 
exposure at the outer membrane surface provides binding sites 
for coagulation factors and promotes formation of factor Xa 
and thrombin by facilitating assembly of tenase and prothrom-
binase complexes.12,13
In other cell types, cell membrane scrambling14,15 and 
degranulation16 are modified by ceramide producing acid 
sphingomyelinase (ASM). Sphingomyelinases break down 
membrane sphingomyelin with ceramide production and play 
© 2013 American Heart Association, Inc.
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Objective—Platelet activation is essential for primary hemostasis and acute thrombotic vascular occlusions. On activation, 
platelets release their prothrombotic granules and expose phosphatidylserine, thus fostering thrombin generation 
and thrombus formation. In other cell types, both degranulation and phosphatidylserine exposure are modified by 
sphingomyelinase-dependent formation of ceramide. The present study thus explored whether acid sphingomyelinase 
participates in the regulation of platelet secretion, phosphatidylserine exposure, and thrombus formation.
Approach and Results—Collagen-related peptide–induced or thrombin-induced ATP release and P-selectin exposure were 
significantly blunted in platelets from Asm-deficient mice (Smpd1−/−) when compared with platelets from wild-type 
mice (Smpd1+/+). Moreover, phosphatidylserine exposure and thrombin generation were significantly less pronounced 




 activation and aggregation, as well as 
activation-dependent Ca2+ flux, were not significantly different between Smpd1−/− and Smpd1+/+ platelets. In vitro thrombus 
formation at shear rates of 1700 s−1 and in vivo thrombus formation after FeCl
3
 injury were significantly blunted in Smpd1−/− 
mice while bleeding time was unaffected. Asm-deficient platelets showed significantly reduced activation-dependent 
ceramide formation, whereas exogenous ceramide rescued diminished platelet secretion and thrombus formation caused 
by Asm deficiency. Treatment of Smpd1+/+ platelets with bacterial sphingomyelinase (0.01 U/mL) increased, whereas 
treatment with functional acid sphingomyelinase-inhibitors, amitriptyline or fluoxetine (5 μmol/L), blunted activation-
dependent platelet degranulation, phosphatidylserine exposure, and thrombus formation. Impaired degranulation and 
thrombus formation of Smpd1−/− platelets were again overcome by exogenous bacterial sphingomyelinase.
Conclusions—Acid sphingomyelinase is a completely novel element in the regulation of platelet plasma membrane 
properties, secretion, and thrombus formation.  (Arterioscler Thromb Vasc Biol. 2014;34:61-71.)
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an important role in lipid signaling of different cardiovascular 
diseases resulting in vascular inflammation.17 Ceramides form 
ceramide-rich platforms thus increasing membrane curvature 
and eventual fusion and fission of vesicles.18 Ceramide partici-
pates in vascular inflammation and thrombosis by triggering 
exocytosis of Weibel–Palade bodies from endothelial cells, an 
effect inhibited by exogenous NO.19 ASM is a key regulator of 
T-lymphocyte granule secretion, degranulation, vesicle shed-
ding, and especially phosphatidylserine-exposing micropar-
ticle release from glial cells.16,20 By producing ceramide, ASM 
may trigger cell membrane scrambling with phosphatidylser-
ine exposure and thus suicidal death of other blood cells, such 
as erythrocytes.21,22
ASM activity and ceramide formation thus contribute to the 
pathophysiology of a wide variety of disorders, including ath-
erosclerosis,23–25 inflammation, fibrosis and infection,26 cystic 
fibrosis,26–28 Wilson disease,22 diabetes mellitus,29 cardiovascu-
lar disease,30,31 cerebral ischemia,32 multiple sclerosis33 major 
depression,14 Parkinson disease,34 and Alzheimer disease.14 
Tricyclic antidepressant medications, such as amitriptyline 
or fluoxetine, are widely used as experimental functional 
ASM-inhibitors.35
Although it is known that platelets secrete ASM on throm-
bin stimulation,36,37 nothing is known about the role of ASM in 
platelet physiology. The present study thus explored the role 
of ASM in platelet function. To this end, platelets have been 
isolated from gene-targeted mice lacking functional ASM 
(Smpd1−/−) and from their wild-type littermates (Smpd1+/+).
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
To study the functional role of ASM in the regulation of plate-
let function, platelets were isolated from gene-targeted mice 
lacking functional Asm (Smpd1−/−) and their respective wild-
type littermates (Smpd1+/+).
Smpd1−/− mice did not exhibit spontaneous bleeding. Blood 
platelet counts and mean platelet volume were similar in 
Smpd1+/+ and Smpd1−/− mice (Table), indicating that Asm 
is not essential for platelet generation. No differences were 
found in other hematologic parameters (Table). Furthermore, 
transmission electron microscopy of Asm-deficient platelets 
revealed no significant morphological differences and espe-
cially no difference in number and morphology of α-granules 
and dense granules when compared with platelets from wild-
type mice (Figure I in the online-only Data Supplement).
To elucidate the effect of Asm on platelet secretion, the 
activation-dependent release of platelet α (P-selectin expo-
sure) and dense granules (ATP release) was quantified before 
and after platelet stimulation with CRP or thrombin. As 
illustrated in Figure 1A, P-selectin abundance at the plate-
let surface after stimulation with low concentrations of CRP 
(0.1 and 1.0 μg/mL) and thrombin (0.005 U/mL) was signifi-
cantly lower in Smpd1−/− platelets than in Smpd1+/+ platelets. 
Degranulation after stimulation with high concentrations of 
CRP (5 μg/mL; data not shown) or thrombin (0.02 U/mL) 
was not significantly different. To explore the effect of Asm 
on degranulation of platelet dense granules further, activa-
tion-dependent ATP release was determined in Smpd1+/+ and 
Smpd1−/− platelets. The increase of ATP concentration in the 
supernatant after stimulation with lower concentrations of 
CRP (0.5 and 1 μg/mL) or thrombin (0.005 and 0.02 U/mL) 
was significantly diminished in Smpd1−/− platelets as com-
pared to Smpd1+/+ platelets (Figure 1C and 1D). At high CRP 
(≥5 μg/mL) or thrombin (0.1 U/mL) concentrations, no sig-
nificant difference was found.
Although the activation-dependent platelet secretion was 





 activation (Figure 1B) and aggregation (Figure 1E 
and 1F), after low dose and high dose of thrombin or CRP 
stimulation were not significantly different in Smpd1+/+ and 
Smpd1−/− platelets.
To examine the role of Asm in activation-dependent plate-
let phosphatidylserine exposure after cell membrane scram-
bling and induction of the coagulation cascade by activation 
of prothrombinase complexes, phosphatidylserine exposure 
(annexin-V binding) and thrombin generation were quan-
tified before and after platelet stimulation (Figure 2). The 
effect of Asm on activation-dependent platelet cell mem-
brane scrambling with procoagulant phosphatidylserine 
exposure was determined by flow cytometric analysis of 
platelet annexin-V binding after stimulation with thrombin 
(1 U/mL) or a combination of thrombin (0.01 U/mL) and 
CRP (5 μg/mL). As shown in Figure 2A, activation-depen-
dent phosphatidylserine exposure was significantly blunted 
in Asm-deficient platelets than in wild-type platelets. In a 
further series of experiments, we found that thrombin gen-
eration is significantly affected in Smpd1−/− platelets. As 
illustrated in Figure 2B through 2D, platelet-rich plasma 
from Asm-deficient mice displayed significantly reduced 
peak levels of thrombin generation, whereas thrombin lev-
els in platelet-poor plasma were similar in Smpd1−/− and 
Smpd1+/+ mice.
Platelet activation, degranulation, and subsequent throm-
bus formation are triggered by an increase of intracellular 




Table.  Blood Count of Smpd1+/+ and Smpd1−/− mice
Smpd1+/+ Smpd1−/−
Platelets, ×103/μL 1097±39 1105±108
MPV, fl 6.6±0.1 6.4±0.1
Erythrocytes, ×106/μL 7.7±0.7 7.9±0.5
HGB, g/dL 11.2±1.1 11.8±0.9
HCT, % 37.2±4.6 38.2±4.0
MCV, fl 48.4±1.8 49.2±1.5
Arithmetic mean±SEM (n=8) of platelet count, mean platelet volume (MPV), 
red blood cell (RBC) count (erythrocytes), hemoglobin concentration (HGB), 
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Ca2+ concentration ([Ca]2+
i
), which is accomplished by Ca2+ 
store depletion and store operated Ca2+ entry. In theory, ASM 
could have an effect on degranulation, phosphatidylserine 
exposure, and thrombus formation by modifying [Ca]2+
i
. 
However, spectrofluorimetric measurements revealed that 
activation-dependent [Ca]2+
i
 increases were similar in 
Smpd1−/− platelets and in Smpd1+/+ platelets after stimulation 
with CRP or thrombin (Figure IIB in the online-only Data 
Figure 1. Activation-dependent release of α-granules and dense granules, integrin αIIbβ3 activation, and aggregation in platelets from 
Smpd1−/− and Smpd+/+ mice. A, Arithmetic means±SEM (n=6) of P-selectin exposure determined by flow cytometry in platelets from 
Smpd1+/+ (black bars) and Smpd1−/− (gray bars) mice in response to collagen-related peptide (CRP; μg/mL) or thrombin (U/mL) at the 
indicated concentrations. B, Arithmetic means±SEM (n=6) of activated integrin αIIbβ3 determined by flow cytometry in platelets from 
Smpd1+/+ (black bars) and Smpd1−/− (gray bars) mice in response to CRP (μg/mL) or thrombin (U/mL) at the indicated concentra-
tions. C, CRP-dependent ATP release from Smpd1+/+ and Smpd1−/− platelets. Original tracings (top) and arithmetic means±SEM (n=6; 
bottom) illustrating ATP concentration in the supernatant after stimulation of platelets from either Smpd1+/+ (black bars) or Smpd1−/− 
(gray bars) mice with CRP. D, Thrombin-dependent ATP release from Smpd1+/+ and Smpd1−/− platelets. Original tracings (top) and 
arithmetic means±SEM (n=6; bottom) illustrating the ATP concentration in the supernatant after stimulation of platelets from either 
Smpd1+/+ (black) or Smpd1−/− (gray) mice with thrombin. E, Aggregation: representative tracings of aggregometry after stimulation 
of platelets from either Smpd1+/+ (black) or Smpd1−/− (gray) mice with either 1 μg/mL CRP (top) or 0.005 U/mL thrombin (bottom). 
F, Arithmetic means±SEM (n=6) of aggregometry after stimulation of platelets from either Smpd1+/+ (black bars) or Smpd1−/− (gray 
bars) mice with either CRP (μg/mL) or thrombin (U/mL) at the indicated concentrations. *P<0.05 and **P<0.01 indicate statistically 
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Supplement). Furthermore, as shown in Figure IIA in the 
online-only Data Supplement, Asm deficiency did not appre-
ciably influence intracellular Ca2+ release or store operated 
Ca2+ entry induced in Smpd1+/+ and Smpd1−/− platelets with 
sarco/endoplasmic reticulum (SR/ER) Ca2+ ATPase pump 
inhibitor thapsigargin.
To elucidate the relevance of Asm in pathological thrombus 
formation, we examined in vitro platelet adhesion and throm-
bus formation to collagen-coated surfaces under flow at low 
(500 s−1) and high (1700 s−1) wall shear rates. As illustrated 
in Figure 3A, Smpd1+/+ platelets formed massive and dense 
thrombi after 5 minutes of perfusion. At shear rates of 500 
s−1, no significant reduction of thrombus formation was found, 
but at high arterial shear rates Smpd1−/− platelets formed only 
smaller single thrombi with a significantly reduced thrombus 
surface coverage (Figure 3A and 3B). Real-time imaging of 
thrombus formation under flow by capturing images of flu-
orescent-labeled platelets indicated a consistent and gradual 
increase in fluorescence intensity from deposited Smpd1+/+ 
platelets (Figure 3E). With Smpd1−/− blood, the slope of fluo-
rescence increase was diminished, and time traces pointed to a 
slow, but gradual thrombus buildup. Notably, time traces from 
none of the experiments or inspection of consecutive images 
showed evidence for increased thrombus instability or embo-
lization events with Smpd1−/− blood.
To assess the significance of Asm for arterial thrombus 
formation in vivo, time to occlusion of mesenteric arterioles 
caused by thrombus formation after FeCl
3
-induced injury 
have been analyzed. As shown in Figure 3C and 3D, vas-
cular occlusion caused by arterial thrombus formation was 
significantly impaired in Smpd1−/− mice. Nevertheless, the 
tail bleeding time was nearly unaffected in Asm-deficient 
mice (Figure 3F).
Because Asm has been identified as critical enzyme regu-
lating ceramide production, we examined the activation-
dependent ceramide formation in Smpd1−/− platelets. As a 
result, we found significantly impaired ceramide formation 
in Asm-deficient platelets when compared with wild-type 
platelets on stimulation with thrombin or the combination of 
thrombin and CRP (Figure 4A). In a further series of experi-
ments, we tried to restore the ceramide defect in Smpd1−/− 
platelets by the addition of exogenous ceramide C16. As 
illustrated in Figure 4, addition of exogenous ceramide res-
cued the defective granule secretion (Figure 4B and 4C), as 
well as the blunted thrombus formation of Smpd1−/− platelets 
(Figure 4D and 4E) up to a level comparable with that of 
wild-type platelets.
In the next step, we explored the effect of pharmacologi-
cal ASM inhibition with amitriptyline (5 μmol/L) in wild-
type mouse platelets (Figure 5). The increase of α-granule 
Figure 2. Activation-dependent proco-
agulant activity of Smpd1−/− and Smpd+/+ 
platelets. A, Activation-dependent phos-
phatidylserine exposure of Smpd1+/+ and 
Smpd1−/− platelets. Arithmetic means±SEM 
(n=6) of phosphatidylserine exposure 
(annexin-V) determined by flow cytometry 
in platelets from Smpd1+/+ (black bars) and 
Smpd1−/− (gray bars) mice in response to 
thrombin (thr) (1.0 U/mL) and thrombin/ 
collagen-related peptide (CRP; 0.01 U/mL/ 
5 μg/mL). B, Activation-dependent thr 
generation of Smpd1+/+ (black bars) and 
Smpd1−/− (gray bars) platelets. Arithmetic 
means±SEM (n=6) of thr peak and endog-
enous thrombin potential (ETP) (% from 
wild type) in platelet-poor plasma (PPP) 
and platelet-rich plasma (PRP) in the pres-
ence or in the absence of CRP (5 μg/mL). 
C, Representative thr generation tracings 
in PPP from either Smpd1+/+ (black) or 
Smpd1−/− (gray) mice. D, Representative 
thr generation tracings in PRP from either 
Smpd1+/+ (black) or Smpd1−/− (gray) mice 
in the presence (bottom) or in the absence 
(top) of CRP (5 μg/mL). *P<0.05 and 
**P<0.01 indicate statistically significant dif-
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Figure 3. Formation and stability of 
thrombi formed by Smpd1−/− and 
Smpd+/+ platelets, arterial thrombotic 
occlusion in vivo, and tail bleed-
ing time in Smpd1-/- and Smpd+/+ 
mice. A, Original phase-contrast 
images of surface coverage by 
adherent platelets after perfusion 
of whole blood from Smpd1+/+ (top) 
and Smpd1−/− (bottom) mice over a 
collagen-coated surface for 5 min-
utes at low (500 s−1, left) and high 
(1700 s−1, right) arterial shear rates. 
Scale bar, 50 μm. B, Arithmetic 
means±SEM (n=5) of surface cover-
age by adherent platelets after per-
fusion of whole blood from Smpd1+/+ 
(black bars) and Smpd1−/− (gray 
bars) mice over a collagen-coated 
surface for 5 minutes at low (500 s−1, 
left) and high (1700 s−1, right) arte-
rial shear rates. *P<0.05 indicates 
statistically significant difference. 
C, Representative images of occlu-
sive in vivo thrombus formation 0, 
5, 10, and 20 minutes after injury 
of mesenteric arterioles with FeCl3 
in Smpd1+/+ (left) and Smpd1−/− 
(right) mice. Scale bar, 50 μm. 
D, Arithmetic means±SEM (n=10) 
of time to arterial occlusion after 
FeCl3-induced injury of mesenteric 
arterioles in Smpd1+/+ (black bar) and 
Smpd1−/− (gray bar) mice. **P<0.01 
indicates statistically significant dif-
ference. E, Arithmetic means±SEM 
(n=4) of integrated fluorescence 
(FL) intensity of adherent platelets 
after perfusion of whole blood from 
Smpd1+/+ (black diamonds) and 
Smpd1−/− (gray diamonds) mice over 
a collagen-coated surface represent-
ing thrombus growth and stability 
in vitro >5 minutes. F, Tail bleeding 
time measured after amputating 
the tail tip of Smpd1+/+ (black dots) 
and Smpd1−/− (gray dots) mice. 
Each dot represents 1 individual; 
black bar represents the mean 
value (n=12; P=0.21). n.s. indicates 
nonsignificant.
secretion (P-selectin exposure; Figure 5A) and dense gran-
ule secretion (ATP release; Figure 5C and 5D) after stimula-
tion with lower concentrations of CRP (0.1 and 1 μg/mL) 
or thrombin (0.005–0.02 U/mL) was significantly decreased 
in the presence of the functional Asm inhibitor amitripty-
line (5 μmol/L). At high CRP (≥ 5 μg/mL) or thrombin (0.1 
U/mL) concentrations, degranulation tended to be lower 
in the presence than in the absence of amitriptyline; how-
ever, the difference did not reach statistical significance 
(data not shown). Phosphatidylserine exposure after platelet 
stimulation with thrombin (1.0 U/mL) or the combination 
of thrombin (0.01 U/mL) and CRP (5 μg/mL) was signifi-
cantly diminished after preincubation with amitriptyline (5 
μmol/L) when compared with solvent control (Figure 5B). 
Similar observations were made in arterial thrombus forma-
tion at shear rates of 1700 s−1 after inhibition of ASM with 
5 μmol/L amitriptyline. As illustrated in Figure 5E, thrombi 
formed by Smpd1+/+ platelets after 5-minute perfusion were 
significantly blunted in the presence of amitriptyline (5 
μmol/L), whereas amitriptyline showed no further effect on 
reduced thrombus formation of Smpd1−/− platelets.
Nearly the same results as with amitriptyline were obtained 
with fluoxetine, a second functional pharmacological inhibitor 
of ASM (Figure 6). At concentrations of 5 μmol/L, fluoxetine 
inhibited activation-dependent platelet secretion at low ago-
nist concentrations of thrombin (0.005 U/mL) and CRP (0.5 
and 1.0 μg/mL), as well as the thrombus formation at high 
arterial shear rates (Figure 6C).
Opposite effects were observed in the presence of 0.01 
U/mL bacterial ASM (Figure 7). The increase of P-selectin 
exposure (Figure 7A) and ATP release (Figure 7C and 7D) 
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and 1 μg/mL) or thrombin (0.005 U/mL) were significantly 
increased in the presence of bacterial sphingomyelinase 
(bSM; 0.01 U/mL). At high CRP (≥ 5 μg/mL) or thrombin 
(0.1 U/mL) concentrations, degranulation again tended to be 
higher in the presence than in the absence of bacterial ASM; 
however, the difference did not reach statistical significance 
(data not shown). A significantly increased phosphatidylser-
ine exposure was observed in thrombin-stimulated platelets 
(1.0 U/mL) or the combination of thrombin (0.01 U/mL)- 
and CRP (5 μg/mL)-stimulated platelets after treatment 
with bSM when compared with solvent control treatment 
(Figure 7B).
Exposure of the platelets to bSM (0.01 U/mL) significantly 
augmented platelet secretion, phosphatidylserine exposure, 
and formation of thrombi in Smpd1−/− platelets up to the 
values observed in wild-type platelets (Figure 8). In detail, 
bSM rescued defective activation-dependent ATP release on 
stimulation with CRP (0.5 μg/mL) or thrombin (0.005 U/
mL) (Figure 8A and 8B), as well as CRP-/thrombin-trig-
gered phosphatidylserine exposure (Figure 8C) and thrombus 
formation at 1700 s−1 (Figure 8D and 8E). Moreover, bSM 
significantly increased platelet secretion on low agonist stim-
ulation, cell scrambling, and thrombus formation at high arte-
rial shear rates.
Discussion
The present study discloses an important role of ASM in 
the regulation of platelet secretion and initiation of platelet 
procoagulant activity. According to the present observations, 
Asm does not appreciably alter agonist-induced increases of 




 activation or aggre-
gation, but critically enhances activation-dependent platelet 
degranulation and platelet-dependent thrombin generation 
after activation-dependent exposure of platelet phosphati-
dylserine, resulting in enhanced arterial thrombus forma-
tion. Similar to genetic knockout of ASM, pharmacological 
inhibition of the enzyme with the functional inhibitors ami-
triptyline or fluoxetine blunted ATP release and thrombus 
formation. Conversely, ATP release and thrombus formation 
were augmented in the presence of bSM.
Figure 4. Ceramide formation and the 
role of ceramide in defective secretion 
and thrombus formation in Smpd1−/− and 
Smpd1+/+ platelets. A, Activation-depen-
dent ceramide production of Smpd1+/+ 
(black bars) and Smpd1−/− (gray bars) 
platelets after stimulation with thrombin 
(thr; 1 U/mL) or the combination of thr  
(0.1 U/mL) and collagen-related peptide 
(CRP; 5 μg/mL). Arithmetic means±SEM 
(n=6) of ceramide formation (% from wild 
type) in washed platelets are shown. 
B, Arithmetic mean±SEM (n=6) illustrating 
the ATP concentration in the supernatant 
after stimulation with 0.5 μg/mL CRP of 
platelets from Smpd1+/+ (black bars) and 
Smpd1−/− (gray bars) mice in the absence 
(left) or presence (right) of ceramide C16 
(1 μmol/L). C, Arithmetic means±SEM 
(n=6) illustrating the ATP concentra-
tion in the supernatant after stimulation 
with 0.005 U/mL thr of platelets from 
Smpd1+/+ (black bars) and Smpd1−/− (gray 
bars) mice in the absence (left) or pres-
ence (right) of ceramide C16 (1 μmol/L). 
D, Arithmetic means±SEM (n=5) of sur-
face coverage by adherent platelets after 
perfusion of whole blood from Smpd1+/+ 
(black bars) and Smpd1−/− (gray bars) 
mice in the absence (left) or presence 
(right) of 1 μmol/L ceramide C16 over a 
collagen-coated surface for 5 minutes at 
a shear rate of 1700 s−1. E, Original repre-
sentative phase-contrast images of sur-
face coverage by adherent platelets after 
perfusion of whole blood from Smpd1+/+ 
and Smpd1−/− mice in the absence or 
in the presence of 1 μmol/L ceramide 
C16 over a collagen-coated surface for 
5 minutes at a shear rate of 1700 s−1. 
Scale bar, 50 μm. **P<0.01 and *P<0.05 
indicate statistically significant difference 
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The decreased activation-dependent granule secretion 
and phosphatidylserine exposure in Smpd1−/− platelets paral-
leled their impaired ability to generate adhesion to collagen-
coated surfaces under high arterial shear rates in vitro and 
defective arterial thrombus formation in vivo without affect-
ing stability of formed thrombi. Interestingly, the effect of 
CRP and thrombin on P-selectin exposure and ATP release 
was apparent only at low concentrations of the agonists. 
Increasing the agonist concentration dissipated the differ-
ences between Smpd1−/− and Smpd1+/+ platelets, indicating 
that Asm deficiency decreases the sensitivity of platelets 
to activating agonists but does not modify platelet function 
after maximal activation.
Although Asm-deficient platelets showed a significantly 
diminished activation-dependent secretion, number and mor-
phology of α-granules and dense granules of Smpd1−/− plate-
lets were normal and comparable with platelets from wild-type 
mice, indicating that the observed effects are not because of a 
regulatory role of Asm in platelet granules biogenesis.
Interestingly, the defects in secretion and phosphatidyl-
serine exposure of Smpd1−/− platelets were obviously not 
secondary to altered increases of cytosolic Ca2+ because 
activation-dependent increase of [Ca]2+
i
 and store operated 
Ca2+ entry were found to be similar in Smpd1−/− and Smpd1+/+ 
platelets. This is a remarkable finding because platelet 
secretion and phosphatidylserine exposure are known to be 
Ca2+-dependent and, accordingly, suggest that a potential 
signaling defect is downstream of phospholipase C activa-





and platelet aggregation were insensitive to sphingomyelin-
ase deficiency.
As shown previously38 Asm modifies the organization of 
the plasma membrane and thus participates in the release 
of cytotoxic granules in T-lymphocytes.16 Indeed, the cel-
lular process of degranulation and vesiculation is connected 
with membrane fusion and fission. Asm may have an effect 
on platelet function by modifying the membrane turnover 
through the hydrolysis of sphingomyelin.39 Lack of Asm leads 
to the reorganization of membrane microdomains.39 The Asm 
product ceramide participates in the formation of lipid rafts 
and cholesterol-enriched membrane microdomains, providing 
a platform for signaling pathways, such as redox signaling.40 
Figure 5. Activation-dependent platelet 
secretion, phosphatidylserine exposure, 
and thrombus formation of Smpd1+/+ plate-
lets in the absence and in the presence of 
amitriptyline. A, Arithmetic means±SEM 
(n=6) of P-selectin exposure determined by 
flow cytometry in platelets from Smpd1+/+ 
mice in the absence (black bars) and pres-
ence (gray bars) of amitriptyline (5 μmol/L) 
in response to collagen-related peptide 
(CRP; μg/mL) or thrombin (thr; U/mL) at 
the indicated concentrations. B, Activation-
dependent phosphatidylserine exposure 
of Smpd1+/+ platelets in the absence and 
in the presence of 5 μmol/L amitriptyline. 
Arithmetic means±SEM (n=6) of phospha-
tidylserine exposure (annexin-V) deter-
mined by flow cytometry in platelets from 
Smpd1+/+ mice in the absence (black bars) 
and in the presence (gray bars) of amitripty-
line (5 μmol/L) in response to thr (1.0 U/mL) 
or thr/CRP (0.01 U/mL/5 μg/mL). C, Origi-
nal tracings (top) and arithmetic means 
(bottom)±SEM (n=6) of ATP concentra-
tion in the supernatant after stimulation of 
platelets from Smpd1+/+ mice with CRP in 
the absence (black) or presence (gray) of 
amitriptyline (5 μmol/L). D, Original tracings 
(top) and arithmetic means (bottom)±SEM 
(n=6) illustrating the increase of ATP 
concentration in the supernatant after 
stimulation of platelets from Smpd1+/+ mice 
with thrombin in the absence (black) or 
presence (gray) of amitriptyline (5 μmol/L). 
E, Arithmetic means (left)±SEM (n=8) and 
original phase-contrast images (right) 
of surface coverage by adherent plate-
lets after perfusion of whole blood from 
Smpd1+/+ (left) and Smpd1−/− (right) mice 
in the absence (black bars) and in the pres-
ence (gray bars) of amitriptyline (5 μmol/L) 
over a collagen-coated surface for 5 
minutes at a shear rate of 1700 s−1. Scale 
bar, 50 μm. *P<0.05 and **P<0.01 indicate 
statistically significant difference from 
Smpd1+/+ platelets treated with the solvent 
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As ceramide increases the curvature and the bending rigidity 
of the membrane,18,41 it can change the membrane properties 
and, therefore, influence the degranulation of cells. Because 
platelets cannot accomplish de novo synthesis of ceramide,42 
platelets do depend on their sphingomyelinase activity for 
ceramide production. Sphingomyelinase mediated ceramide 
generation occurs within seconds,43 thus influencing rapid acti-
vation-dependent cellular functions. As shown in the present 
study, the ASM seems to play a major role in platelet ceramide 
metabolism because Smpd1−/− platelets showed a significantly 
decreased ceramide production. Furthermore, we could show 
that exogenous ceramide was able to rescue the phenotype of 
defective platelet secretion and thrombus formation.
Asm-dependent regulation of platelet secretion and phos-
phatidylserine exposure could result from direct regulation of 
platelet membrane property. As a matter of fact, Asm-deficient 
platelets showed a significant reduction in activation-depen-
dent thrombin generation because of reduced exposure of 
phosphatidylserine, the assembly sites for tenase and pro-
thrombinase complexes. Notably, reduced thrombin genera-
tion was only found in Asm-deficient platelet-rich plasma, 
whereas platelet-poor plasma of Smpd1−/− mice showed no 
differences in thrombin levels when compared with that of 
wild-type samples.
Tricyclic antidepressant medications, including amitripty-
line or fluoxetine, are widely used functional experimental 
inhibitors of Asm because it has been shown that these cat-
ionic amphiphiles trigger proteolysis of Asm, resulting in a 
significantly reduced Asm activity.38 Treatment with amitrip-
tyline or fluoxetine at concentrations of 5 μmol/L leads to an 
effective inhibition of Asm activity44 because granule secre-
tion and phosphatidylserine exposure after stimulation of 
platelets with CRP or thrombin were significantly impaired 
in the presence of amitriptyline or fluoxetine, a finding similar 
to that in Asm-deficient platelets. Treatment of platelets with 
amitriptyline showed no further inhibitory effect on impaired 
thrombus formation of Smpd1−/− platelets, confirming that 
there are no significant further targets of amitriptyline affect-
ing platelet function unrelated to Asm inhibition, even though 
we cannot rule out that amitriptyline and fluoxetine exert addi-
tional small effects in platelets.
The addition of bSM could mimic the effect of Asm on 
platelet degranulation and phosphatidylserine exposure. The 
stimulation-dependent secretion of platelet α-granules and 
dense granules shown by P-selectin exposure, ATP release, 
and phosphatidylserine translocation to the outer leaflet of 
the plasma membrane was significantly increased in the 
presence of bSM.
According to the present observations, Asm activity 
emerged as a critical determinant of platelet function and 
thrombus formation. Activation of Asm is thus expected to 
enhance the activation-dependent platelet degranulation and 
phosphatidylserine translocation by modifying membrane 
properties. ASM is upregulated or activated by a wide vari-
ety of mediators, including thrombin,37 platelet-activating 
factor,30 amyloid,45,46 and plasminogen activator inhibitor 1.47 
Pathophysiologically, ASM plays a major role in vascular 
inflammation and the development of atherosclerosis31 by reg-
ulating the release of Weibel–Palade bodies from stimulated 
endothelial cells.19 According to the present study, Asm might, 
Figure 6. Activation-dependent platelet 
secretion and thrombus formation of 
Smpd1+/+ platelets in the absence and 
in the presence of fluoxetine. A, Origi-
nal tracings (top) and arithmetic means 
(bottom)±SEM (n=6) of ATP concentra-
tion in the supernatant after stimulation of 
platelets from Smpd1+/+ mice with colla-
gen-related peptide (CRP) in the absence 
(black) or in the presence (grey) of fluox-
etine (5 μmol/L). B, Original tracings (top) 
and arithmetic means (bottom)±SEM 
(n=6) illustrating the increase of ATP 
concentration in the supernatant after 
stimulation of platelets from Smpd1+/+ 
mice with thrombin in the absence (black) 
or in the presence (gray) of amitriptyline (5 
μmol/L). C, Arithmetic means (left)±SEM 
(n=8) and original phase-contrast images 
(right) of surface coverage by adherent 
platelets after perfusion of whole blood 
from Smpd1+/+ mice in the absence (black 
bars) and in the presence (gray bars) of 
amitriptyline (5 μmol/L) over a collagen-
coated surface for 5 minutes at a shear 
rate of 1700 s−1. Scale bar, 50 μm. 
**P<0.01 and *P<0.05 indicate statisti-
cally significant difference from Smpd1+/+ 
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in part, be effective by regulating platelet secretion that plays 
an active part in vascular inflammation and atherogenesis.1,4
After rupture of atherosclerotic lesions with endothelial 
denudation, circulating platelets are exposed to thrombogenic 
subendothelial collagen resulting in platelet recruitment to 
the injured vessel wall.48 Platelets adhering to collagen, for 
example, via glycoprotein VI, expose phosphatidylserine at 
their outer surface and produce phosphatidylserine-exposing 
membrane blebs and microvesicles propagating the coagu-
lation process by facilitating the assembly and activation of 
tenase and prothrombinase complex.49 This conversion of acti-
vated platelets to a procoagulant state, referring to the abil-
ity of platelets to support thrombin generation, is associated 
with specific biochemical and morphological changes, some 
of which are similar to those occurring in apoptotic cells.50
Platelets with impaired Asm are less prone to undergo col-
lagen-triggered thrombus formation under high shear stress, 
a property reversed by adding ceramide or (bacterial) sphin-
gomyelinase. Along those lines, treatment with the functional 
Asm inhibitors, amitriptyline and fluoxetine, significantly 
reduced shear stress–induced thrombus formation on collagen.
Platelet degranulation and phosphatidylserine exposure, as 
described in this article to be modified by Asm, are expected 
to be the central mechanism underlying thrombus formation 
under high arterial shear stress.11,51 In line with these findings, 
the present study unravels that Asm-dependent regulation of 
platelet membrane properties, secretion, and platelet-driven 
thrombin generation plays a significant role for arterial throm-
bus formation in vivo. Asm-deficient mice were found to be 
protected against arterial thrombotic occlusion in a model 
of arterial thrombus formation in mesenteric arterioles after 
Fe
3
Cl-induced injury where thrombus formation is highly 
thrombin dependent.52 Accordingly, enhanced activity of ASM 
could increase platelet responsiveness and platelet-dependent 
thrombin generation, thus predisposing to thrombotic compli-
cations, such as ischemic stroke. Conversely, genetic or phar-
macological knockout of ASM may be a therapeutic option to 
decrease the susceptibility to thrombotic complications. As a 
matter of fact, Asm-deficient mice displayed a significantly 
reduced infarct size and a better behavioral outcome after 
cerebral ischemia.32
Despite the strong effect of Asm deficiency on degranula-
tion, as well as thrombin generation and thrombus formation, 
we could, surprisingly, not observe a significant effect of Asm 




 activation and aggrega-
tion. In line with these findings, even though thrombus buildup 
is significantly impaired, thrombus stability is unaffected in 
Smpd1−/− mice. The possibility remains that Asm and Asm-
dependent ceramide production may affect platelet membrane 
structure directly and are involved in the signaling cascade 
triggering platelet secretion and phosphatidylserine exposure 




 activation and 
aggregation. Further studies will be required to define whether 
the respective signaling pathways dissociate.
Figure 7. Activation-dependent 
P-selectin exposure and ATP 
release from Smpd1+/+ platelets in 
the absence and in the presence of 
bacterial sphingomyelinase (bSM). 
A, Arithmetic means±SEM (n=6) 
of P-selectin exposure determined 
by flow cytometry in platelets from 
Smpd1+/+ mice in presence (gray 
bars) or absence (black bars) of 
bSM (0.01 U/mL) in response to 
collagen-related peptide (CRP) 
or thrombin (thr) at the indicated 
concentrations. B, Activation-
dependent phosphatidylserine 
exposure of Smpd1+/+ platelets in 
the absence and in the presence of 
bSM. Arithmetic means±SEM (n=6) 
of phosphatidylserine exposure 
(annexin-V binding) determined by 
flow cytometry in platelets from 
Smpd1+/+ mice in the absence 
(black bars) and in the presence 
(gray bars) of bSM (0.01 U/mL) 
in response to thr (1.0 U/mL) and 
thr/CRP (0.01 U/mL/5μg/mL). 
C, Original tracings (top) and arith-
metic means (bottom)±SEM (n=6) 
illustrating the ATP concentration 
in the supernatant after stimula-
tion of platelets from Smpd1+/+ 
mice with CRP in the absence 
(black) or in the presence (gray) of 
bSM (0.01 U/mL). D, Original trac-
ings (top) and arithmetic means 
(bottom)±SEM (n=6) illustrating the increase of ATP concentration in the supernatant after stimulation of platelets from Smpd1+/+ 
mice with thr in the absence (black) or in the presence (gray) of bSM (0.01 U/mL). **P<0.01 and *P<0.05 indicate statistically signifi-
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In conclusion, the present observations identify ASM as a 
novel regulator of platelet degranulation and thrombus forma-
tion. Thus, inhibition of ASM may prove useful in the treat-
ment of thrombosis.
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Platelet activation is essential for primary hemostasis and acute arterial thrombosis. In other cell types, both degranulation and phosphatidylserine 
exposure are modified by sphingomyelinase-dependent formation of ceramide. Platelet secretion and membrane scrambling with phosphatidylserine 
exposure are crucial to development of arterial thrombosis. The present study thus explored whether acid sphingomyelinase participates in ceramide-
dependent regulation of platelet membrane properties and procoagulatory activity. According to the present observations, acid sphingomyelinase 
plays a decisive role in activation-dependent platelet secretion, phosphatidylserine exposure, and thrombin generation. Acid sphingomyelinase thus 
participates in signaling mechanisms of platelet adhesion and arterial thrombus formation in vivo. Conversely, treatment with functional acid sphin-
gomyelinase-inhibitors, amitriptyline or fluoxetine, blunted activation-dependent platelet degranulation, phosphatidylserine exposure, and thrombus 
formation. This study identifies a complete novel signaling pathway regulating platelet membrane properties and function, which has potential thera-
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